Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cytora Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter is being reviewed by 1 distinct examiner within 1 distinct art unit. GRABER, JAMES J is the busiest examiner for the portfolio, with 1 pending action currently under their supervision.
The concentration of the pending office action under the distinct examiner reflects a narrow scope of current prosecution activity. Because the busiest examiner pending count is 1, GRABER, JAMES J is managing all of the company's immediate patent office responses. The limitation to 1 distinct art unit suggests that the portfolio's active legal developments are restricted to a specific technical classification within the broader biotechnology field.
For a practitioner, this profile indicates that the outcome of the current prosecution depends entirely on the interpretation of a single examiner. The lack of diversity in the art units means there is no opportunity to leverage different examination standards across the portfolio. Strategy should be tailored to the specific historical preferences of GRABER, JAMES J, as this individual holds the only active matter for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18909327 | METHODS FOR TREATING NEUROLOGICAL DISEASES | GRABER, JAMES J | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18909327 | METHODS FOR TREATING NEUROLOGICAL DISEASES | GRABER, JAMES J | 1631 | §103§112DP | Non-Final OA | — | Pending | Oct 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCytora Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
James J Graber has the most, with 1 of Cytora Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
